Immunohistochemical detection of cell-cycle associated markers on paraffin embedded and formalin fixed needle biopsies of prostate cancer: Correlation of p120 protein expression with AgNOR, PCNA/Cyclin, KI-67/MIB1 proliferation-scores and gleason gradings

European Journal of Histochemistry

Volumn 42, Issue 1, 1998, Pages 41-48

  Botticelli, A R ^a   Casali, A M ^b   Botticelli, L ^a   Zaffe, D ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

AgNOR; P120 nucleolar protein; Proliferating cell nuclear antigens; Proliferation nucleolar associated antigen; Prostate cancer

Indexed keywords

EID: 0031959282     PISSN: 1121760X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Bocker, T., Bittinger A , Wieland W., Buettner R., Fauser G., Hofstaedter F., and Rüschoff J.: In vitro and ex vivo expression of nucleolar proteins B23 and p120 in benign and malignant epithelial lesions of the prostate. Mod, Pathol. 8, 226-231, 1995.
2. Bolton W.E, Freeman J.W., Mikulka W.R., Healy G.G., Schmittling R.J. and Kenuon N.S.: Expression of proliferation-associated antigens (PCNA. p120, p145) during the re-entry of GO cells into the cell cycle. Cytometry 17, 66-74, 1994.
3. Botticelli, A.R.: Rassegna e stato attuale dei fattori prognostici del carcinoma prostatico. Bol. Soc, Med. Chir. Pavia 108, 327-335,1994.
4. Botticelli A.R., Criscuolo M., and Martinelli A.M.: Prognostic value of AgNOR in prostatic carcinomas. Pathol. Res. Pract. 187, 661, 1991.
5. Botticelli A.R., Criscuolo M., Martinelli A.M., Botticelli L., and Filini A.: Proliferating cell nuclear antigen/cyclin in incidental carcinoma of the prostate. Virchows Arch. A. 423, 365-368, 1993.
6. Botticelli A.R. Marandola P., Jallous H., Vicini D., Migaldi M., Speroni A., and Mirando P.. Quantitative and qualitative AgNORs rates of prostate cancer on needle biopsies: a multicentric study. Pathologica 87, 624-630,1995.
7. Botticelli A.R., Martinelli A.M., and Botticelli L.: Morphochromatic analysis of cell nuclear markers in human tumours. USA Microscopy & Analysis, 40, 13-14, 1996.
8. Bravo R., Macdonald-Bravo H.: Changes in the nuclear distribution of cyclin (PCNA) but not its synthesis depend upon DNA replication. E.M.B.O. J. 4, 655-661, 1985.
9. Chiusa L., Formiconi A., Galliano D., Di Primio O., and Pich A.: AgNORs nuclear and nucleolar morphometry in prostate carcinoma. Proceedings of the Fourth International Workshop on Application of AgNORs in Pathology. 27-29 September 1996, Taormina (Italy) Eur. J. Histochem. 40, 337, 1996.
10. Crocker J : Nucleolar organiser regions. In: Underwood, JCE, ed, "Pathology of the nucleus," Springer Verlag, Berlin, 91-149, 1990.
11. Daskal I., and Trerè D.: AgNOR quantity in needle biopsies of prostate adenocarcinomas: correlation with proliferation rate, Gleason score, clinical stage and DNA content. Proceedings of the Fourth International Workshop on Application of AgNORs in Pathology. 27-29 September 1996, Taormina (Italy) Eur. J. Histochem. 40, 338, 1996.
12. Derenzini M.: AgNOR proteins in neoplastic pathology. Proceedings of the Fourth International Workshop on Application of AgNORs in Pathology. 27-29 September 1996, Taormina (Italy) Eur. J. Histochem. 40, 338, 1996.
13. Derenzini M., Pession A., and Trerè D.: The quantity of nucleolar silver-stained proteins is related to proliferating activity in cancer cells. Lab. Invest. 63, 137-140, 1990.
14. Derenzini M., and Ploton D.: Interphase nuclear organizer regions in cancer cells. Int. Rev Exp. Pathol. 32, 149-192, 1991.
15. Derenzini M., Sirri V., and Trerè D.: Nucleolar organizer regions in tumor cells. J. Cancer 7, 71-77, 1994.
16. Derenzini M., and Trerè D.: Importance of interphase nucleolar organizer regions in tumor pathology. Vichows Arch. B Cell Pathol. 61, 1-8, 1991.
17. Derenzini M., Trerè D., Chieco P., and Melchiorri C.: Interphase AgNOR quantity is not related to DNA content in 11 established human cancer cell lines. Exp. Cell Res. 211, 282-285, 1994.
18. Ferrari A.R., Blanchi F.M., and Migliorini L.: Proposta di un metodo di valutazione semiquantitativa dell AgNORs (RAP score). Pathologica 85, 661-665, 1993.
19. Fonagy A., Swiderski C., and Freeman J.W.: Nucleolar p120 is expressed as a delayed early response gene and is inducible by DNA-damaging agents. J. Cell Physiol. 164, 634-643, 1995.
20. Freeman J.W., Busch R.K., Gyorkey F., Ross B.E., and Busch H.: Identification and characterization of a human proliferating-associated nucleolar antigen with molecular weight of 120,000 expressed in early G1 phase. Cancer Res. 48, 1244-1251, 1988.
21. Galle M.P.W, Visser De Jong E., Ten Kate F.J.W., Schroeder F.H., and van der Kwast T.H.: Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer. J. Urol. 142, 1342-1425, 1989.
22. Gerdes J., Lemke H., Baisch H., Wacker H.H., Schwab U., and Stein H.: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133, 1710-1715, 1984.
23. Gleason D.F.: Histologic grading of prostate cancer. A prospective. Human Pathol. 23, 273-279, 1992.
24. Grignon D.J., and Hammond E.H. for the Conferees Partiecipating in the Prostate Cancer Working Group: College of American pathologists conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the prostate cancer working group. Arch. Pathol. Lab. Med. 119, 1122-1126, 1995.
25. Hansen A.B., and Ostergard B.: Nucleolar organizer regions in hyperplastic and neoplastic prostatic tissue. Virchows Arch. A 417, 9-13, 1990
26. Harper M.E., Glynne-Jones E., Goddard L., Wilson D.W., Matenhelia S.S., Conn I.G., Peeling W.B., and Griffiths K.: Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. Prostate 20, 243-253, 1992.
27. Laroye G.J.: Is the frequency of mitoses and PCNA positive cells in tissues affected by delay in fixation? Lessons for accurate tumor grading. Pathology 28, 328-333, 1996.
28. Losi L., Botticelli A.R., Criscuolo M., Filoni A., and Roncaglia R.: DNA ploidy in incidental carcinoma of the prostate. In. J. Biol. Markers 6, 76, 1991.
29. Mamaeva S., Lundgren R., Elfvint P., Limon J , Mandhal N., Mamaev N., Hendrkson H., Heim S., and Mitelman F.: AgNOR staining in benign hyperplasia and carcinoma of the prostate. Prostate 18, 155-162, 1991.
30. Marandola P., Lardennois B., Ploton D., Derenzini M., Trerè D., Campo B., Corrada P., Valentino V., Roggia A., Broggini P., Vicini D., Francescetti G.P., Iweha C., and Speroni A.: Nucleolar organizer regions: preliminary results of the clinical use of a new marker for prostatic carcinoma (40 cases). Eur. Urol. 21, 71-74, 1992:
31. Meyer J.S., Sufrin G., and Martin S.A.: Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labelling. J. Urol. 128, 1353-1356, 1982.
32. Nemoto R., Uchida K., Shimazui T., Hattori K., Koiko K., and Harada M.: Immunocytochemical demonstrations of S phase cells by anti-bromodeoxyuridine monoclonal antibody in human prostate cancer. J. Urol. 141, 337-340, 1989.
33. Nilsson S., Nordgren H., Eköv S., and Lögdöhl M.: Expression of Ki-67 -a proliferating associated antigen - in human prostatic cancer. Acta Oncol. 30, 177-179, 1991.
34. Oomens E.H.G.M., van Steenbrugge G.J., van der Kwast T.H., and Schröder F.K.: Application of the monoclonal antibody Ki-67 on prostate biopsies to assess the proliferative cell fraction of human prostatic carcinoma. J. Urol. 145, 81-85, 1991.
35. Pich A., Chiusa L., Pisani P., Krengli M., Pia F., and Navone R.: Argyrophilic nucleolar organizer region counts and proliferating cell nuclear antigen scores are two reliable indicators of survival in pharyngeal carcinoma. J. Cancer Res. Clin. Oncol. 119, 106-110, 1992.
36. Ploton D., Menager M., Jeannesson P., Himber G., Pigeon F., and Adnet J.J.: Improvement in the staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level. Histochem. J. 18, 5-14, 1986.
37. Ring K., Karp F.S., Olsson C.A., O'Toole K., Bixon R., and Benson M.C.: Flow cytometric analysis of localized adenocarcinoma of the prostate: the use of archival DNA analysis in conjunction with pathological grading to predict clinical out-come following radical retropubic prostatectomy. Prostate 17, 155-164, 1990.
38. Risio M., and Rossini F.P.: Cell proliferation of colorectal adenomas containing invasive carcinomas. Anticancer Res. 13, 43-47, 1993.
39. Rüschoff J.. Nukleolus organisierende Regionen (NORs) in der pathomorphologischen Tumordiagnostik. G. Fischer Verlag. Stuttgart, Jena. New York, 1992.
40. Rüschoff J., Bocker T., Buettner R., Bittinger A., Wieland W., and Hofstaedter F.: In vitro und ex vivo Expression nukleoiärer proliferationsassoziierter Antigene (p120, B23) in der Prostata. In vitro and ex vivo expression of nucleolar proliferation-associated antigens (p120, B23) in the prostate. Verh. Dtsch. Ges. Pathol, 77, 103, 1993.
41. Rüschoff J., Schmidt C , and Endi E.: Expression and biological effects of the nucleolar protein p120 - An update. Proceedings of the Fourth International Workshop on Application of AgNORs in Pathology. 27-29 September 1996, Taormina (Italy) Eur. J Histochem. 40, 359, 1996.
42. Shivji K.K., Kenny M.K., and Wood R.D.: Proliferating cell nuclear antigen (PCNA) is required for DNA excision repair. Cell 69, 367-374, 1992.
43. Skopelitou A., Korkolopoulou P., Papanicolaou A., Christodoulou P., Thomas-Tsagli E., and Pavlakis K.: Comparative assessment of proliferating cell nuclear antigen immunostaining and of nucleolar organizer region staining in transitional cell carcinomas of the urinary bladder. Correlation with other conventional prognostic pathologic parameters. Eur. Urol. 22, 235-240, 1992.
44. Trerè D., Ceccarelli C., Danova M., and Derenzini M.: In vivo bromodeoxyuridine labelling index, AgNOR protein expression and DNA content in human tumours. Eur. J. Histochem. 40, 17-26, 1996.
45. Visokorpi T.: Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma. J. Pathol. 168, 7-13, 1992.